Status Updates on Ongoing and Planned HIV Prevention Trials

The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.

How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.

Ongoing Studies for the Treatment and Prevention of the COVID-19 Virus

This table is a work in progress, as this is an incredibly dynamic landscape. Over the past month, the scientific community has accelerated development of COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of resources available to track these developments.

In addition, a collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration and Treatment Action Group offers concise overviews and analyses of key research areas.

COVID-19 Resources for Advocates

This document is to help advocates with links to the latest information about COVID-19, including information on its prevention, transmission, relationship to HIV and research that’s underway. Many of the links below are constantly updated so please click through for the latest.

Picking Up the Pace

PrEP introduction is gaining traction around the world. Check out AVAC’s graphic showing global totals, and the uptick in implementation studies, regulatory approvals, global recommendations and more. 

AIDS Vaccines by the Numbers: Trials, discoveries, money and more

We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.

Margarita Breakfast Club Session 1: Arrested Development: Discontinuation of the MOSAICO Trial, its Legacy and Expectations for HIV Vaccine Research

Monday, February 20 at 7:00–8:00am PT

AVAC, the CROI Community Liaison Subcommittees, European AIDS Treatment Group, and other partners hosted virtual Margarita Breakfast Clubs (MBCs) for the 2023 CROI meeting. Speaker details, recording, and resources for the first 2023 MBC below.

  • Moderator: Ntando Yola, Desmond Tutu HIV Foundation
  • Speakers: Dr. Susan Buchbinder, San Francisco Department of Public Health, Richard Jefferys, Treatment Action Group

Recording / Slides

Margarita Breakfast Club Session 3: The Data Gap: Filling in the Missing Perspectives on Women and Children in HIV Research

Wednesday, February 22 at 7:00–8:00am PT

AVAC, the CROI Community Liaison Subcommittees, European AIDS Treatment Group, and other partners hosted virtual Margarita Breakfast Clubs (MBCs) for the 2023 CROI meeting. Speaker details, recording, and resources for the third 2023 MBC below.

  • Moderator: Dawn Averitt, The Well Project, Women’s Research Initiative on HIV/AIDS
  • Speakers: Professor Lee Fairlie, WITS RHI, Imelda Mahaka, Pangaea Zimbabwe AIDS Trust, Jane Kabami, Infectious Diseases Research Collaboration Uganda

Recording / Resources

Margarita Breakfast Club Session 2: Moving Forward: Upcoming Strategies on STI Prevention

Tuesday, February 21 at 7:00–8:00am PT

AVAC, the CROI Community Liaison Subcommittees, European AIDS Treatment Group, and other partners hosted virtual Margarita Breakfast Clubs (MBCs) for the 2023 CROI meeting. Speaker details, recording, and resources for the second 2023 MBC below.

  • Moderator: Jim Pickett, AVAC
  • Speakers: Dr. Jean-Michel Molina, University of Paris Cité, Jonathan Ayala, NMAC, CROI Community Educator Scholar

Recording / Slides

COMPASS Africa Newsletter (February 2023)

Year End Newsletter

In this issue: five end of the year SPARC stories, eight topline findings from the coalition health score card, in-country strategy labs and the all COMPASS strategy lab.

Re: Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection

AVAC submits comment and response to the United States Preventative Services Task Force (USPSTF) Draft Recommendation statement for PrEP. The USPSTF recommended an “A” Grade for PrEP that includes CAB for PrEP.